Although the combination of a MEK inhibitor and a PD-L1 inhibitor recently failed to show compelling efficacy in a pivotal clinical trial of colorectal cancer (IMblaze370), a tumor type for which MEK inhibition and immune checkpoint therapy have no meaningful activity in unselected patients, MEK inhibitors continue to be studied as a means of sensitizing tumors to immune checkpoint therapy in multiple other tumor types, particularly those in which immunotherapy has some single agent activity [22]. Here, CD274 is linked to neoplasm.